Immunoediting Driven by Therapy and the Development of Cancer Immune Evasion
-
By
-
Shuang Meng
-
Zibo Wang
-
September 4, 2026
Clinical Scorecard: Immunoediting Driven by Therapy and the Development of Cancer Immune Evasion
At a Glance
| Category | Detail |
|---|
| Condition | Cancer Immunoediting |
| Key Mechanisms | Therapy-induced immune activation, selective bottleneck, genetic alterations, therapy-resistant stem-like states. |
| Target Population | Patients undergoing anticancer treatment. |
| Care Setting | Oncology |
Key Highlights
- Anticancer treatments can select for immune-evasive tumor populations.
- Therapy-induced immunoediting involves elimination, equilibrium, and escape phases.
- Longitudinal biomarkers may help detect residual equilibrium and guide treatment adaptation.
- Resistance mechanisms include primary, adaptive, and acquired forms.
- Therapeutic pressure can reveal tumor vulnerabilities while establishing evolutionary bottlenecks.
Guideline-Based Recommendations
Diagnosis
- Assess tumor visibility and immune response dynamics.
Management
- Consider longitudinal tissue sampling and circulating tumor DNA for monitoring.
Monitoring & Follow-up
- Utilize dynamic biomarkers to identify evolving immune escape.
Risks
- Evaluate treatment-related fatigue and physical deconditioning.
Patient & Prescribing Data
Patients with heterogeneous malignant-cell populations.
Therapies exert distinct immune-selective pressures, influencing tumor evolution.
Clinical Best Practices
- Implement strategies for early detection of immune escape.
- Adapt treatment based on evolving tumor and immune dynamics.
Related Resources & Content
